Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after

Jin M Cheng1, K Martijn Akkerhuis, Olivier Meilhac

  • 1From the Erasmus MC, Department of Cardiology, Rotterdam, The Netherlands (J.M.C., K.M.A., R.M.O., H.M.G.-G., R.-J.v.G., P.W.S., E.B., I.K.); INSERM U698, Bichat Hospital, Paris, France (O.M.); CHU de La Reunion, Saint-Denis, La Reunion, France (O.M.); UMR3145 CNRS Bio-Rad, Sysdiag Laboratory, Montpellier, France (D.P., D.M., E.d.P., P.G., J.F.); INSERM, Université Pierre et Marie Curie, Centre de Recherche des Cordeliers, Paris, France (F.J.); INSERM, Centre d'Investigations Cliniques 9501 and INSERM U1116, Nancy, France (P.R.); CHU Nancy, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France (P.R.); and Université de Lorraine, Lorraine, France (P.R.).

Abstract